

This symposium is supported by:



Roche AB, Box 1228, 171 23 Solna. Telefon 08-726 12 00. www.roche.se

WELCOME

As chairmen of the coming Precison Medicine Breast Cancer Symposium, it is our pleasure to invite you to join us on October 3, 2018, at Elite Park Avenue, Gothenburg.

Diagnosis and treatment of breast cancer

The objectives of the symposium is precision medicine today and in ten years time, with focus on breast cancer. It includes improving our understanding of breast cancer biology and will increase our knowledge on how to treat breast cancer patients. Furthermore, we also aim to communicate the latest developments and future predictive markers of breast cancer.

The symposium is multidisciplinary, oriented towards physicians, researchers, pathologists and others involved in the understanding, analysis, diagnosis, and treatment of breast cancer.

You will hear a distinguished group of oncology experts give cutting-edge presentations on Precision Medicine Breast Cancer and other relevant therapy-predictive factors. These are highly topical issues and the data presented will undoubtedly inspire much discussion and interaction between presenters and participants alike.

We invite you to join us in Gothenburg – to contribute to this Precision Medicine Breast Cancer Symposium and help advance the diagnosis and treatment of breast cancer.

Sincerely,

MD PhD Ana Bosch Professor Jonas Bergh

Lunds Universitet Karolinska Institutet, Stockholm

Information

If you have any questions or would like additional information about the symposium, please contact Akademikonferens, email: pmbc2018@akademikonferens.se

Registration

Registration must be carried out by using the link:

reg.akademikonferens.se/pmbc2018

no later than September 21

If the number of registrations for the symposium exceeds the number of places available, places will be allocated with a view to achieving a balanced regional spread.

The symposium is free of charge but if you fail to appear without reporting it, you will be charged a cost of SEK 500

PROGRAM

Designation and live of

12.30	Registration and lunch
14.00-14.10	Welcome and introduction MD PhD Ana Bosch, Professor Jonas Bergh
14.10-14.35	ER intra-tumor heterogeneity and how that may influence prognosis in breast cancer patients. Ass Prof Linda Lindström
14.35-15.00	Genomic tumor heterogeneity in the metastatic perspective. Ass Prof Johan Hartman
15.00-15.10	Discussion
15.10-15-40	How to use different tools to best identify relevant subtypes of breast cancer. MD PhD Aleix Prat
15.40-15.50	Discussion
15.50-16.20	Coffee break
16.20-16-40	Definitions of endocrine resistance; Can we do better in characterization and definitions? Professor Per-Eystein Lönning
16.40-17.10	Artificial intelligence applied to tissue analytics. Professor Johan Lundin
17.10-17.20	Discussion
17.20-17.40	How to implement treatment innovations and follow up Professor Jonas Bergh
17.40-18.00	General discussion and conclusions MD PhD Ana Bosch, Professor Jonas Bergh
18:00 -	Dinner